Last synced from Twitter 7h ago
Prospects for a safe COVID-19 vaccine
Rapid development of an efficacious vaccine against the viral pathogen SARS-CoV-2, the cause of the coronavirus disease-2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on...
Accommodating individual travel history and unsampled diversity in Bayesian phylogeographic inference of SARS-CoV-2
Spatiotemporal sampling gaps in existing pathogen genomic data limits their use in understanding epidemiological patterns. Here, the authors apply a phylogeographic approach with SARS-CoV-2 genomes to accurately reproduce pathogen spread by...
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists.
However, direct systematic comparisons of COVID-19 with other critical illnesses...
Laboratory Supply Shortages Are Impacting COVID-19 and Non-COVID Diagnostic Testing | ASM.org
The shortage of laboratory supplies associated with the high demand for COVID-19 testing have been continuously impacting the laboratory supply chain since the early days of the pandemic. Now, new reports of concerning and unprecedented supply...
The three Vs needed to end this pandemic
While scientific and vaccine manufacturing community make huge strides in the race towards that goal, it is important to remember that vaccines are only one of three Vs needed to beat this coronavirus.
Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evolution
The combination of phenotypic measures of antigenic drift and genotypic measures of functional constraint improves the accuracy of long-term seasonal influenza A/H3N2 forecasts.
Immunity and Re-Infection
For months now, people have been watching closely to see if it's possible to get re-infected with the coronavirus. It's taken a while for the signal-to-noise to get better, but by now there's no doubt that the answer is yes, it's possible. We've...
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Understanding immune responses to severe acute respiratory syndrome coronavirus 2
is crucial to understanding disease pathogenesis and the usefulness of bridge therapies,
such as hyperimmune globulin and convalescent human plasma, and to developing...
'Near extinction' of influenza in NZ as numbers drop due to lockdown
Mask wearing and social distancing for Covid-19 has all but cut influenza cases in New Zealand this year, with only six flu isolates detected in this country from April to August. Professor Michael Baker offers his analysis.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
The COVID-19 pandemic presents an urgent health crisis. Human neutralizing antibodies (hNAbs) that target the host ACE2 receptor-binding domain (RBD) of the SARS-CoV-2 spike1–5 show therapeutic promise and are being evaluated clincally6–8. To...
Do cross-reactive antibodies cause neuropathology in COVID-19?
Neurological symptoms are increasingly being observed in patients with COVID-19; this Comment article considers whether cross-reactive antibodies might contribute to the pathology associated with SARS-CoV-2 infection.
Intercellular telomere transfer extends T cell lifespan
The common view is that T-lymphocytes activate telomerase, a DNA polymerase that extends telomeres at chromosome ends, to delay senescence. We show that independently of telomerase, T cells elongate telomeres by acquiring telomere vesicles from...
SARS-CoV-2 Cluster in Nursery, Poland
We report a cluster of surprisingly high spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with a single nursery in P...
Berry Consultants Webinar on SARS-COV-2 Vaccine Trials - Berry Consultants
On Friday, October 2 at 11am US Eastern (4pm UK), Berry Consultants October FACTS webinar will be on SARS-COV-2 vaccine trials and opened to the broader public to attend. Dr. Kert Viele of Berry Consultants will present on the recently released...
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein
The ‘D614G’ mutation (Aspartate-to-Glycine change at position 614) of the SARS-CoV-2 spike protein has been speculated to adversely affect the efficacy of most vaccines and countermeasures that target this glycoprotein, necessitating frequent...
Relatives of rubella virus in diverse mammals
Ruhugu virus and rustrela virus are the first close relatives of rubella virus, providing insights into the zoonotic origin of rubella virus and the epidemiology and evolution of all three viruses.
Using viral load and epidemic dynamics to optimize pooled testing in resource constrained settings
Extensive virological testing is central to SARS-CoV-2 containment, but many settings face severe limitations on testing. Group testing offers a way to increase throughput by testing pools of combined samples; however, most proposed designs have not...
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
In general, neuropathological changes in patients with COVID-19 seem to be mild, with
pronounced neuroinflammatory changes in the brainstem being the most common finding.
There was no evidence for CNS damage directly caused by SARS-CoV-2. The...